Japanese encephalitis: Update on vaccines and vaccine recommendations

Current Opinion in Infectious Diseases

Volumn 23, Issue 5, 2010, Pages 426-431

  Wilder Smith, A ^a   Halstead, Sb ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Research Program   (United States)

Author keywords

Advisory committee on immunization practices; chimeric Japanese encephalitis vaccine; flavivirus; inactivated Japanese encephalitis vaccine IC51; Japanese encephalitis; travelers

Indexed keywords

CHIMERIVAX JAPANESE; IC 51; INACTIVATED VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

AUSTRALIA; DRUG APPROVAL; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC ENCEPHALITIS; EUROPE; HUMAN; REVIEW; RISK BENEFIT ANALYSIS; SEROCONVERSION; SOUTHEAST ASIA; TRAVEL; UNITED STATES; VACCINATION;

ASIA; AUSTRALIA; ENCEPHALITIS, JAPANESE; EUROPE; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; TRAVEL; UNITED STATES; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 77956225996     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833c1d01     Document Type: Review

References (44)

1. Halstead SB, Thomas SJ. Japanese encephalitis: new options for active immunization. Clin Infect Dis 2010; 50:1155-1164.
2. Hills SL, Van Cuong N, Touch S, etal. Disability from Japanese encephalitis in Cambodia and Viet Nam. J Trop Pediatr 2010 [Epub ahead of print].
3. Halstead SB, Jacobson J. Japanese encephalitis vaccines. In: Plotkin SA, Orenstein WAand Offit P, editors. Vaccines. Philadelphia: Saunders Elsevier; 2008.
4. Hanna JN, Ritchie SA, Phillips DA, etal. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Aust 1996; 165:256-260.
5. Japanese encephalitis vaccines: WHO position paper. Wkly Epidemiol Rec 2006; 81: 331-340
6. Liu W, Gibbons RV, Kari K, et al. Risk factors for Japanese encephalitis: a case-control study. Epidemiol Infect 2010 [Epub ahead of print].
7. Konishi E, Suzuki T. Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 2002; 21 (1-2):98-107.
8. Tsai TF. Flaviviruses. In: Mandell GL, Bennett JE and Dolin R., editors. Principles and practice of infectious diseases, vol.2, 6th ed. Philadelphia: Elsevier; 2005. pp. 1930-1941.
9. Konishi E, Kitai Y, Tabei Y, et al. Natural Japanese encephalitis virus infection among humans in west and east Japan shows the need to continue a vaccination program. Vaccine 2010; 28:2664-2670.
10. Solomon T, Ni H, Beasley DW, et al. Origin and evolution of Japanese encephalitis virus in southeast Asia. J Virol 2003; 77:3091-3098.
11. MaSP, YoshidaY, Makino Y, et al. Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan. Am J Trop Med Hyg 2003; 69:151-154.
12. Konishi E, Yamaoka M, Khin Sane W, et al. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus pre-membrane and envelope genes. J Virol 1999; 73:5527-5534.
13. Sukhavachana P, Yuill TM, Russell PK. Assay of arbovirus neutralizing antibody by micro methods. Trans R Soc Trop Med Hyg 1969; 63:446-455.
14. Li P, Cao RB, Zheng QS, et al. Enhancement of humoral and cellular immunity in mice against Japanese encephalitis virus using a DNA prime-protein boost vaccine strategy. Vet J 2010; 183:210-216.
15. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin Biol Ther 2009; 9:921-931.
16. Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am 2003; 23:665-697.
17. Plesner AM, Arlien-Soborg P, Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet 1996; 348:202-203.
18. Centers for disease control, inactivated Japanese encephalitis vaccine. Recommendations of the Advisory Commitee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep, 1993; 42: 1-15.
19. Liu ZL, Hennessy S, Strom BL, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997; 176:1366-1369.
20. Hennessy S, Liu Z, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996; 347:1583-1586.
21. Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 2009; 360:1465-1466.
22. WHO. Global Advisory Committee on Vaccine Safety 9-10 June 2005. Wkly Epidemiol Rec 2005; 28: 242-243.
23. Tandan JB, Ohrr H, Sohn YM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007; 25:5041-5045.
24. Wilder-Smith A, Freedman DO. Japanese encephalitis: is there a need for a novel vaccine? Expert Rev Vaccines 2009; 8:969-972.
25. Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632-649.
26. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20 (7-8):1004-1018.
27. Monath TP, Levenbook I, Soike K, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 2000; 74:1742-1751.
28. Bhatt TR, Crabtree MB, Guirakhoo F, et al. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg 2000; 62:480-484.
29. Lobigs M, Larena M, Alsharifi M, et al. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol 2009; 83:2436-2445.
30. TauberE, Kollaritsch H, KorinekM, etal. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: anoninferiority, phase III, randomised controlled trial. Lancet 2007; 370:1847-1853.
31. Tauber E, Kollaritsch H, von Sonnenburg F, etal. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008; 198:493-499.
32. Schuller E, Klade CS, Wolfl G, et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009; 27:2188-2193.
33. Kaltenbock A, Dubischar-Kastner K, Schuller E, et al. Immunogenicity and afety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 28:834-839.
34. Schuller E, Jilma B, Voicu V, etal. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51. Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008; 26:4382-4386.
35. Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol 2002; 267:105-138.
36. Yaich M. Investing in vaccines for developing countries: how public-private partnerships can confront neglected diseases. Hum Vaccin 2009; 5:368-369.
37. Burchard GD, Caumes E, Connor BA, et al. Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med 2009; 16:204-216.
38. Japanese encephalitis vaccines: recommendations of the Advisory Commitee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:1-21.
39. Leder K, Tong S, Weld L, etal. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2006; 43:1185-1193.
40. Japanese encephalitis among three U.S. travelers returning from Asia, 2003-2008. MMWR Morb Mortal Wkly Rep 2009; 58: 737-740.
41. Mathur A, Tandon HO, Mathur KR, et al. Japanese encephalitis virus infection during pregnancy. Indian J Med Res 1985; 81:9-12.
42. Wittesjo B, Eitrem R, Niklasson B, et al. Japanese encephalitis after a 10-day holiday in Bali. Lancet 1995; 345:856-857.
43. Buhl MR, Black FT, Andersen PL, Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. Scand J Infect Dis 1996; 28:189.
44. Kaltenbock A, Dubischar-Kastner K, Eder G, etal. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine 2009; 27:4483-4489.